Jump to Navigation

Facebook Connect

User login

NLA Guidelines, Recommendations and Statements

Jun, 2011

In connection with the Familial Hypercholesterolemia ("FH") initiative of the Foundation of the National Lipid Association, the NLA held a consensus conference in January 2011 to bring together experts on FH for the generation of an NLA statement of clinical guidance regarding the diagnosis and treatment FH. The link above provides the Executive Summary of the NLA expert panel, published in the June 2011 edition of the Journal of Clinical Lipidology.

Oct, 2008

As healthcare professionals, the membership of the National Lipid Association (NLA) pays close attention to stories about medicine and treatment that impact public opinion. Our members are frequently asked to comment on controversial findings, and the Association offers the following comment on a recent study, the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. This was a clinical trial of a drug (Vytorin) that combines two lipid-lowering drugs (ezetimibe and simvastatin).

Jul, 2008

Overview: The results of a study published in the June 15, 2008 issue of the American Journal of Cardiology suggest that there may be significant benefits of Xuezhikang, a specific red yeast rice extract. The National Lipid Association (NLA) recommends that physicians and patients be aware that the composition of this product is not yet fully known and that future use of this product will depend on the result of additional ongoing studies. The NLA offers the following opinion and advice to its membership with respect to this trial.*

Jan, 2008

The limitations of the ENHANCE study, in terms of its design and the patients studied, are such that physicians should not alter their prescribing policies at this time. Current discussion regarding the ENHANCE Study is not based upon published work subject to peer review and thus cannot yet be evaluated by the medical community.

Apr, 2006

In an effort to address concerns about using lipid-altering therapies, the NLA appointed a Safety Assessment Task Force to evaluate the safety of statin and statin combination therapy. The link above provides the statement of the NLA expert panel, published in the April 17, 2006 supplement to The American Journal of Cardiology.

Mar, 2006

In the second publication of the NLA Safety Assessment Task Force, the experts address the safety of nonstatin therapy. The link above provides the statement of the NLA expert panel, published in the March 19, 2007 supplement to The American Journal of Cardiology.


by Dr. Radut.